SGMOQ

SEC source: 0001209191-22-014176 · doc4.xml · derivative · entry 2

Schott Robert J. · CIK 0001845310 · SVP, Head of Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,700

Underlying: Common Stock · 110,700 shares

Expires 2032-02-24

F3 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014176 · doc4.xml · nonDerivative · entry 1

Schott Robert J. · CIK 0001845310 · SVP, Head of Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,537

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

F2 · balance_after: Includes 26,668 shares subject to the Reporting Person's February 12, 2021 RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 12, 2023 and 2024, respectively, subject to Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014172 · doc4.xml · derivative · entry 3

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,770

Underlying: Common Stock · 121,770 shares

Expires 2032-02-24

F6 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014172 · doc4.xml · nonDerivative · entry 2

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,993

F5 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014172 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,893

F1 · shares: Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").

F2 · balance_after: Includes: (a) 7,565 shares resulting from the February 25, 2022 sole annual vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 6,304 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 8,335 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, (c) 5,548 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 14,667 shares subject to such RSU grant that will vest in two remaining annual installments of 7,333 shares and 7,334 shares on February 25, 2023 and 2024, respectively, and (see footnote 3)

F3 · balance_after: (d) 3,334 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

F4 · balance_after: Includes 1,953 shares acquired on April 30, 2021 and 692 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan.

SEC source: 0001209191-22-014170 · doc4.xml · derivative · entry 3

Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,700

Underlying: Common Stock · 110,700 shares

Expires 2032-02-24

F6 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014170 · doc4.xml · nonDerivative · entry 2

Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,779

F5 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014170 · doc4.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,779

F1 · shares: Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").

F2 · balance_after: Includes: (a) 3,609 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 5,501 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, (b) 2,999 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 9,167 shares subject to such RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (c) 2,000 shares subject to Reporting Person's March 25, 2020 RSU grant that will vest in two remaining annual installments of 1,000 shares on each of March 25, 2022 and 2023, (d) 1,917 shares subject to Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022 and (see footnote 3)

F3 · balance_after: (e) 7,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in three annual installments of 2,500 shares on each of June 11, 2022, 2023 and 2024. The vesting of all such grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

F4 · balance_after: Includes 426 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan.

SEC source: 0001209191-22-014164 · doc4.xml · derivative · entry 3

Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 604,800

Underlying: Common Stock · 604,800 shares

Expires 2032-02-24

F4 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014164 · doc4.xml · nonDerivative · entry 2

Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 521,176

F3 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014164 · doc4.xml · nonDerivative · entry 1

Macrae Sandy · CIK 0001675687 · Director · President, CEO and Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,176

F1 · shares: Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").

F2 · balance_after: Includes: (a) 10,633 shares resulting from the February 25, 2022 final vesting installment of the Reporting Person's February 25, 2019 RSU grant, (b) 32,756 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 56,261 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023 and (c) 30,173 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 92,254 shares subject to such RSU grant that will vest in two remaining annual installments of 46,120 shares and 46,134 shares on February 25, 2023 and 2024, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014167 · doc4.xml · derivative · entry 3

McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,380

Underlying: Common Stock · 160,380 shares

Expires 2032-02-24

F5 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014167 · doc4.xml · nonDerivative · entry 2

McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,984

F4 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014167 · doc4.xml · nonDerivative · entry 1

McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,584

F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").

F2 · balance_after: Includes: (a) 8,722 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 26,668 shares subject to such RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 25, 2023 and 2024, respectively, and (b) 66,670 shares subject to the Reporting Person's June 25, 2020 RSU grant that will vest in two remaining annual installments of 33,330 shares and 33,340 shares on June 25, 2022 and 2023, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

F3 · balance_after: Includes 900 shares acquired on November 30, 2021 under the Issuer's 2020 Employee Stock Purchase Plan.

SEC source: 0001209191-22-014161 · doc4.xml · derivative · entry 2

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-24

F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014161 · doc4.xml · nonDerivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,700

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014157 · doc4.xml · derivative · entry 2

Smith Karen L. · CIK 0001639637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-24

F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014157 · doc4.xml · nonDerivative · entry 1

Smith Karen L. · CIK 0001639637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,200

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014153 · doc4.xml · derivative · entry 2

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-24

F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014153 · doc4.xml · nonDerivative · entry 1

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,700

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014149 · doc4.xml · derivative · entry 2

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-24

F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014149 · doc4.xml · nonDerivative · entry 1

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,700

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014145 · doc4.xml · derivative · entry 2

Meyers James R · CIK 0001387521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-24

F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014145 · doc4.xml · nonDerivative · entry 1

Meyers James R · CIK 0001387521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,700

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

F2 · balance_after: Includes 1,667 shares subject to the Reporting Person's November 22, 2019 RSU grant that will vest in one final annual installment on November 22, 2022, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014139 · doc4.xml · derivative · entry 2

Markels John · CIK 0001803424 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-24

F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014139 · doc4.xml · nonDerivative · entry 1

Markels John · CIK 0001803424 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,700

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

F2 · balance_after: Includes 1,667 shares subject to the Reporting Person's February 11, 2020 RSU grant that will vest in one final annual installment on February 11, 2023, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014134 · doc4.xml · derivative · entry 2

Hillan Kenneth J. · CIK 0001600359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-24

F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014134 · doc4.xml · nonDerivative · entry 1

Hillan Kenneth J. · CIK 0001600359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,700

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

F2 · balance_after: Includes 10,000 shares subject to the Reporting Person's September 9, 2020 RSU grant that will vest in two remaining annual installments of 5,000 shares on each of September 9, 2022 and 2023, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014126 · doc4.xml · derivative · entry 2

Carey Robert · CIK 0001602064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-24

F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-014126 · doc4.xml · nonDerivative · entry 1

Carey Robert · CIK 0001602064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,700

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

SEC source: 0001209191-22-012765 · doc4.xml · nonDerivative · entry 1

Schott Robert J. · CIK 0001845310 · SVP, Head of Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,537

F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 12, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 11, 2022 of $5.76/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").

F2 · balance_after: Includes 7,869 shares resulting from the February 12, 2022 vesting of the Reporting Person's February 12, 2021 RSU grant and 26,668 shares subject to such RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 12, 2023 and 2024, respectively. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's 2018 EIP through such dates and subject to acceleration as defined in the 2018 EIP.

SEC source: 0000875045-21-000061 · wf-form4_164090233143707.xml · nonDerivative · entry 1

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,152,466

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.53, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0000875045-21-000060 · wf-form4_164069706538898.xml · nonDerivative · entry 2

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,155,230

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0000875045-21-000060 · wf-form4_164069706538898.xml · nonDerivative · entry 1

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,155,830

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.65, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0000875045-21-000059 · wf-form4_163917049537863.xml · nonDerivative · entry 1

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,237,017

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.71, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0000875045-21-000058 · wf-form4_163908412073554.xml · nonDerivative · entry 2

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,260,677

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.735, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0000875045-21-000058 · wf-form4_163908412073554.xml · nonDerivative · entry 1

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,336,491

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.595, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0000875045-21-000057 · wf-form4_163856574488863.xml · nonDerivative · entry 2

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,388,669

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.515, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0000875045-21-000057 · wf-form4_163856574488863.xml · nonDerivative · entry 1

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,390,543

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0000875045-21-000055 · wf-form4_163830723294834.xml · nonDerivative · entry 1

BIOGEN INC. · CIK 0000875045 · 10% owner

Biogen MA Inc. · CIK 0001810387 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Biogen MA Inc.

Disclosed balance after: 24,391,273

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.74, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

SEC source: 0001209191-21-062653 · doc4.xml · nonDerivative · entry 1

Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,455

F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on October 29, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on October 29, 2021 of $8.12/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").

F2 · balance_after: Includes: (a) 265 shares of common stock resulting from the October 29, 2021 vesting of the Reporting Person's November 10, 2020 RSU grant and 405 shares of common stock subject to such RSU grant that will vest in one remaining installment on April 29, 2022; (b) 23,001 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on April 24, 2020 that will vest in two remaining annual installments on April 24, 2022 and 2023 respectively; (continued in Footnote 3)

F3 · balance_after: Continued from Footnote 2 - (c) 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021; and (d) 7,500 shares of common stock subject to RSUs granted to the Reporting Person on August 1, 2021. All such RSUs vest with respect to 1/3rd of the shares granted in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended), through such dates and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-21-051997 · doc4.xml · derivative · entry 2

Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-08-12

F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the August 13, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended), through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-21-051997 · doc4.xml · nonDerivative · entry 1

Willoughby Scott B. · CIK 0001877368 · SVP, Gen. Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,595

F1 · shares: Represents 7,500 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on August 13, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such dates and subject to acceleration as provided in the 2018 EIP, as amended.

F2 · balance_after: Includes: (a) 23,001 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on April 24, 2020; and (b) 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021. All such RSUs vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended), through such dates and subject to acceleration as provided in the 2018 EIP, as amended.

F3 · balance_after: Includes 810 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on November 10, 2020. The RSUs will vest in two equal remaining installments on October 29, 2021 and April 29, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended), through such dates and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-21-043811 · doc4.xml · nonDerivative · entry 1

McClung David Mark · CIK 0001811505 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,294

F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on June 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on June 25, 2021 of $12.02/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").

F2 · balance_after: Includes: (a) 21,805 shares resulting from the June 25, 2021 vesting of the Reporting Person's June 25, 2020 RSU grant and 66,670 shares subject to such RSU grant that will vest in two remaining annual installments on June 25, 2022 and June 25, 2023; (b) 40,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended; and (3) 819 shares acquired by the Reporting Person on May 28, 2021 under the Issuer's 2020 Employee Stock Purchase Plan.

SEC source: 0001209191-21-040405 · doc4.xml · derivative · entry 2

Duraibabu Prathyusha · CIK 0001779092 · SVP, CFO, PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-10

F5 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the June 11, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended.

SEC source: 0001209191-21-040405 · doc4.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · SVP, CFO, PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,827

F1 · shares: Represents 7,500 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 11, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").

F2 · balance_after: Includes: (a) 2,000 shares acquired by the Reporting Person on April 30, 2021 under the Issuer's 2010 Employee Stock Purchase Plan, as amended; and (b) 199 shares acquired by the Reporting Person on May 28, 2021 under the Issuer's 2020 Employee Stock Purchase Plan.

F3 · balance_after: This amount also includes (a) 1,917 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest on April 25, 2022; (b) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; (c) 13,750 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date; and (continued in footnote 4)

F4 · balance_after: (d) 2,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in two remaining annual installments of 1,000 shares each shares on March 25, 2022 and 2023, respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.

SEC source: 0001209191-21-028745 · doc4.xml · nonDerivative · entry 1

Fontenot Jason D. · CIK 0001851761 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,496

F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on April 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on April 23, 2021 of $11.71/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").

F2 · balance_after: Includes: (a) 2,522 shares resulting from the April 25, 2021 vesting of the Reporting Person's April 25, 2019 RSU grant and 3,334 shares subject to such RSU grant that will vest on April 25, 2022; (b) 16,667 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 8,332 shares and 8,335 shares on February 25, 2022 and 2023 respectively; (c) 10,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 which will vest in full on the first anniversary of the grant date; and (continued in footnote 3)

F3 · balance_after: (d) 22,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.

SEC source: 0001209191-21-028744 · doc4.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,128

F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on April 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on April 23, 2021 of $11.71/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").

F2 · balance_after: Includes: (a) 1,254 shares resulting from the April 25, 2021 vesting of the Reporting Person's April 25, 2019 RSU grant and 1,917 shares subject to such RSU grant that will vest on April 25, 2022; (b) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; (c) 13,750 shares subject to the Reporting Person's February 25, 2021 grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date; and (continued in footnote 3)

F3 · balance_after: (d) 2,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in two remaining annual installments of 1,000 shares each shares on March 25, 2022 and 2023, respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.

SEC source: 0001209191-21-023480 · doc4.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,790

F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on March 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on March 25, 2021 of $12.27/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").

F2 · balance_after: Includes: (a) 655 shares resulting from the March 25, 2021 vesting of the Reporting Person's March 25, 2020 RSU grant and 2,000 shares subject to such RSU grant that will vest in two remaining annual installments of 1,000 shares and 1,000 shares on March 25, 2022 and 2023 respectively; (b) 3,833 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; (c) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; and

F3 · balance_after: (d) 44,000 shares subject to the Reporting Person's February 25, 2021 grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.

SEC source: 0001209191-21-028742 · doc4a.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,790

F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on March 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on March 25, 2021 of $12.27/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").

F2 · balance_after: Includes: (a) 655 shares resulting from the March 25, 2021 vesting of the Reporting Person's March 25, 2020 RSU grant and 2,000 shares subject to such RSU grant that will vest in two remaining annual installments of 1,000 shares and 1,000 shares on March 25, 2022 and 2023 respectively; (b) 3,833 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; (c) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; and (continued in Footnote 3)

F3 · balance_after: (d) 13,750 shares subject to the Reporting Person's February 25, 2021 grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.

F4 · balance_after: This Form 4/A is being filed solely to correct the stated amount included in Footnote 3 on the Form 4 filed on behalf of the Reporting Person on March 29, 2021 to be 13,750 shares subject to RSUs vesting which was erroneously reported to be 44,000 shares in such Footnote 3.